/NDRA
NDRA Stock - ENDRA Life Sciences Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$5.16+1.98%
+$0.10 (+1.98%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.44
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $5.68
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NDRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.11 – $5.21
TARGET (TP)$5.93
STOP LOSS$4.75
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.33
52W High$11.96
52W Low$2.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-275,451 | $-234,258 | $-224,415 | $-165,249 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-10,817,147 | $-10,520,735 | $-13,157,559 | $-11,498,305 | $-11,501,917 |
| Net Income | $-11,507,947 | $-10,060,250 | $-13,179,092 | $-11,231,250 | $-11,725,501 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-10.25 | $-5.89 | $-4.57 | $-5.47 | $-12.47 |
Company Overview
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NDRABeat Rate
42%
Last 19 quarters
Avg Surprise
-47493.1%
EPS vs Estimate
Beats / Misses
8/10
1 met exactly
Latest EPS
$-1.75
Q4 2025
EPS Surprise History
Q1 24
-82455.6%
$-297.20vs$-0.36
Q2 24
-168251.9%
$-454.55vs$-0.27
Q3 24
-199700.0%
$-139.86vs$-0.07
Q4 24
+90.6%
$-5.85vs$-62.30
Q1 25
-129.3%
$-9.40vs$-4.10
Q2 25
+33.8%
$-2.59vs$-3.91
Q3 25
+24.7%
$-1.71vs$-2.27
Q4 25
+10.3%
$-1.75vs$-1.95
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-1.95 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-1.95 | $-1.75 | +10.3% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-2.27 | $-1.71 | +24.7% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-3.91 | $-2.59 | +33.8% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-4.10 | $-9.40 | -129.3% | ✗ MISS |
Q4 2024 | Nov 15, 2024 | $-62.30 | $-5.85 | +90.6% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.07 | $-139.86 | -199700.0% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.27 | $-454.55 | -168251.9% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.36 | $-297.20 | -82455.6% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.43 | $-699.30 | -162527.9% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.55 | $-751.75 | -136581.8% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-1783.22 | $-1625.87 | +8.8% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $-1398.60 | $-1818.18 | -30.0% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-2097.90 | $-1748.25 | +16.7% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-1748.25 | $-2097.90 | -20.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-2447.55 | $-2447.55 | 0.0% | = MET |
Q1 2022 | Mar 30, 2022 | $-1.60 | $-2447.55 | -152871.9% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-2447.55 | $-2097.90 | +14.3% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-2447.55 | $-2797.20 | -14.3% | ✗ MISS |
Q2 2021 | May 17, 2021 | $-2447.55 | $-2097.90 | +14.3% | ✓ BEAT |
Latest News
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30
➖ NeutralBenzinga•Dec 8, 2025, 10:16 AM
ENDRA Life Sciences Announces New Results From 2025 TAEUS Liver Device Feasibility Study Showing TAEUS' TAFF Measurement Closely Tracks MRI-PDFF Gold Standard At Critical LFF Thresholds Of 12-17% And 20-22%
📈 PositiveBenzinga•Dec 4, 2025, 01:03 PM•Also: , ,
ENDRA's Updated TAEUS Liver Device Shows MRI-Level Accuracy Across All Stages Of Steatotic Liver Disease In New Feasibility Study
📈 PositiveBenzinga•Nov 20, 2025, 01:09 PM
ENDRA Life Sciences Announces Prelim. Results From Single-Site Clinical Feasibility Study Evaluating TAEUS Liver Device For Quantifying Liver Fat Fraction
📈 PositiveBenzinga•Nov 20, 2025, 01:07 PM
ENDRA Life Sciences Q3 EPS $(2.10) Misses $(1.95) Estimate
📉 NegativeBenzinga•Nov 17, 2025, 01:20 PM
ENDRA Life Sciences Begins Staking Of HYPE Digital Asset Holding
➖ NeutralBenzinga•Nov 13, 2025, 01:02 PM
ENDRA Life Sciences Closes Up To $14.4 Private Placement; Co. Also Announces Purchase Of 78,863.1 HYPE Tokens, Valued At ~$3M, As Part Of Crypto Treasury Strategy
📈 PositiveBenzinga•Oct 23, 2025, 12:06 PM
ENDRA Life Sciences announces at-market private placement of up to $14.4M
➖ NeutralSeeking Alpha•Oct 13, 2025, 12:14 PM
ENDRA Life Sciences Announces $4.9M Private Placement To Launch Arca-Led Crypto Treasury Strategy Focused On DeFi And Perpetual Futures
➖ NeutralBenzinga•Oct 13, 2025, 12:05 PM
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38
➖ NeutralBenzinga•Sep 22, 2025, 09:54 AM
Frequently Asked Questions about NDRA
What is NDRA's current stock price?
ENDRA Life Sciences Inc. (NDRA) is currently trading at $5.16 per share. The stock has moved +1.98% today.
What is the analyst price target for NDRA?
No analyst price targets are currently available for this stock.
What sector is ENDRA Life Sciences Inc. in?
ENDRA Life Sciences Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is NDRA's market cap?
ENDRA Life Sciences Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does NDRA pay dividends?
No, ENDRA Life Sciences Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBBLG
Bone Biologics Corporation
$1.83
Mkt Cap: $0.0B
BGMS
Bio Green Med Solution, Inc.
$1.39
Mkt Cap: $0.0B
BNBX
BNB Plus Corp.
$2.51
Mkt Cap: $0.0B
DHAI
DIH Holding US, Inc.
$0.00
Mkt Cap: $0.0B
GCTK
GlucoTrack, Inc.
$4.74
Mkt Cap: $0.0B
HSCS
HeartSciences Inc.
$2.36
Mkt Cap: $0.0B
ISPC
iSpecimen Inc.
$0.37
Mkt Cap: $0.0B
MOVE
Movano Inc.
$8.39
Mkt Cap: $0.0B
NAOV
NanoVibronix, Inc.
$4.02
Mkt Cap: $0.0B
VERO
Venus Concept Inc.
$1.92
Mkt Cap: $0.0B
Explore stocks similar to NDRA for comparison